What we’re looking for

The Psychiatry Consortium is seeking project proposals which focus on the validation of novel molecular drug-targets for the following mental health conditions:

psychotic disorders, bipolar disorder, depression, anxiety, stress-related disorders, PTSD, OCD, autism spectrum disorders as well as psychiatric symptoms associated with dementia and other cognitive disorders

The Psychiatry Consortium intend to fund projects which:

  • show some evidence that links the molecular target to human disease and of the target modulation having a therapeutic effect, which can be further developed or validated
  • will enable tools for target validation e.g. through optimisation of existing tool compounds to improve selectivity, potency, bioavailability

Projects seeking to identify target modulation biomarkers relevant to disease will also be in scope.

For help determining whether your project is in scope, see our Resources, or if you are interested to find out more about the scope of the call and the funding model, you can watch our latest webinar or contact the Programme Manager.

Next Call:

Coming soon

What we will NOT fund:

  • projects focused on well-studied targets and pathways for psychiatry diseases
  • projects with advanced chemistry e.g. lead/candidate molecules already synthesised and requiring only in vivo PK studies, preclinical proof-of-concept studies or IND-enabling studies
  • non-pharmacological interventions
  • purely academic explorations of new animal or cellular models (unless there is a clear drug discovery application, e.g. using the model as a tool for validating a new target)
  • early target identification studies without a proposed target (i.e. projects that are mostly characterization and/or hypothesis generating studies)
  • repurposing of existing drugs (unless as a method for validating new molecular targets)
  • clinical trials or clinical studies requiring prospective collection of human samples

What we will offer:

The research projects we support are collaborative in nature, with involvement from the Psychiatry Consortium members in devising the final project plan.

The Psychiatry Consortium will provide the successful applicants access to:

  • drug-discovery expertise
  • drug-discovery capabilities, through specialised Partner Organisations
  • commercial know-how
  • project management resources
  • project funding